Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + albumin-bound paclitaxel + platinum agent + recombinant human endostatin
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a four-drug combination regimen consisting of: 1. **Sintilimab** – a fully human IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD‑1), acting as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor immunity. 2. **Albumin-bound paclitaxel** – a nanoparticle formulation of the microtubule inhibitor paclitaxel bound to albumin, which facilitates tumor delivery and reduces solvent-related toxicity; it disrupts mitosis by stabilizing microtubules. 3. **Platinum agent** – typically refers to cisplatin, carboplatin, or oxaliplatin; these are DNA crosslinking agents that induce apoptosis in rapidly dividing cells. 4. **Recombinant human endostatin** – an endogenous angiogenesis inhibitor produced recombinantly, which blocks new blood vessel formation by inhibiting VEGF signaling and binding directly to VEGFR2. The combination leverages immunotherapy, cytotoxic chemotherapy, and antiangiogenic therapy for synergistic antitumor effects in various advanced solid tumors including non-small cell lung cancer and gastric cancer[1][5][6][8].
- Brand names
- Abraxane
- Other names
- nab-paclitaxelrh-endostatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sintilimab + albumin-bound paclitaxel + platinum agent + recombinant human endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + albumin-bound paclitaxel + platinum agent + recombinant human endostatin.